This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments ...

Wells Fargo’s analyst, Mohit Bansal ... 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

JPMorgan lowered the firm’s price target on Regeneron (REGN ... particularly as we near a number of pipeline readouts, the analyst tells investors in a research note. Published first on TheFly ...

This comprehensive analysis examines Regeneron’s current position, future prospects, and the factors that could shape its trajectory in the coming years. Regeneron focuses on developing and ...

On Tuesday, Morgan Stanley (NYSE: MS) adjusted its outlook on Regeneron (NASDAQ: REGN) Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00.Despite the decrease, the firm ...

This comprehensive analysis examines Regeneron’s current position, future prospects, and the factors that could shape its trajectory in the coming years. Regeneron focuses on developing and ...